Skip to main content

Anavex Life Sciences Corp.

AVXL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001314052

No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Anavex Life Sciences Corp. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
108
No complete 13F data for Q4 2020
Shares held
18.2M
No complete 13F data for Q4 2020
Total value
$271.9M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting AVXL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 108 institutions
Q1 2021: 108 institutionsQ2 2021: 127 institutionsQ3 2021: 136 institutionsQ4 2021: 149 institutionsQ1 2022: 139 institutionsQ2 2022: 150 institutionsQ3 2022: 148 institutionsQ4 2022: 139 institutionsQ1 2023: 141 institutionsQ2 2023: 144 institutionsQ3 2023: 143 institutionsQ4 2023: 153 institutionsQ1 2024: 147 institutionsQ2 2024: 141 institutionsQ3 2024: 145 institutionsQ4 2024: 169 institutionsQ1 2025: 181 institutionsQ2 2025: 178 institutionsQ3 2025: 186 institutionsQ4 2025: 186 institutionsQ1 2026: 190 institutionsQ2 2026: 180 institutions
Value heldQ1 2021: $271.9M
Q1 2021: $271.9MQ2 2021: $492.2MQ3 2021: $370.1MQ4 2021: $383.2MQ1 2022: $308.2MQ2 2022: $249.4MQ3 2022: $251.4MQ4 2022: $248.7MQ1 2023: $232.3MQ2 2023: $205.6MQ3 2023: $164.1MQ4 2023: $240.8MQ1 2024: $161.3MQ2 2024: $113.3MQ3 2024: $153.2MQ4 2024: $316.5MQ1 2025: $269.2MQ2 2025: $301.9MQ3 2025: $289.3MQ4 2025: $136.1MQ1 2026: $122.7MQ2 2026: $95.8M
Institutions holding AVXL and their total value by quarter
QuarterHoldersValue
Q2 2026180$95.8M
Q1 2026190$122.7M
Q4 2025186$136.1M
Q3 2025186$289.3M
Q2 2025178$301.9M
Q1 2025181$269.2M
Q4 2024169$316.5M
Q3 2024145$153.2M
Q2 2024141$113.3M
Q1 2024147$161.3M
Q4 2023153$240.8M
Q3 2023143$164.1M
Q2 2023144$205.6M
Q1 2023141$232.3M
Q4 2022139$248.7M
Q3 2022148$251.4M
Q2 2022150$249.4M
Q1 2022139$308.2M
Q4 2021149$383.2M
Q3 2021136$370.1M
Q2 2021127$492.2M
Q1 2021108$271.9M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Anavex Life Sciences Corp..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding AVXL in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Northern Trust Corp653,496$9.77M0.00%––
Great Lakes Advisors, LLC688,892$10.3M0.17%––
Geode Capital Management, LLC1,035,685$15.5M0.00%––
Invesco Ltd.1,125,365$16.8M0.00%––
State Street Corp2,747,179$41.1M0.00%––
Vanguard Group Inc3,393,658$50.7M0.00%––
BlackRock Inc.4,397,565$65.7M0.00%––
Banco Bilbao Vizcaya Argentaria, S.A.10,880––––